Nemaura Medical Inc. announced the next commercialization stage of its proBEAT sensor and AI-based feedback platform, augmenting the BEAT diabetes program. The pilots are intended as a precursor to revenue generating contracts for proBEAT and will commence over the coming weeks and months. The Company is continuing its discussions with corporations and health insurers in the U.S. to further increase the number of pilots that will run in calendar year 2023.

The BEAT diabetes program specifically addresses the growing problem of diabetes and the serious complications associated with the condition, which include heart disease, stroke, blindness, kidney failure, amputation and certain types of cancer. The Centre for Disease Control (CDC) estimate that 37.3 million people have diabetes in the United States (11.3% of the US population). Diabetes is the most expensive chronic condition in the United States: $1 out of every $4 in US health care costs is spent on caring for people with diabetes.

$237 billion is spent each year on direct medical costs and another $90 billion on reduced productivity. There is increasing pressure on program providers to differentiate their programs and increase efficacy. Sensors that can provide feedback on health and wellness enhance both health outcomes and returns on investment for program providers and payers.

To the best of the company’s knowledge, Nemaura’s CGM device is the only non-invasive daily wear sensor presently available and currently approved for use as a Class IIb medical device in Europe. Specifically designed for one day wear, the device removes the need for needle-based testing found in other CGM’s and blood glucose monitoring devices, reducing cost, and making it user-friendly. Pilot studies integrating glucose sensors as part of a general metabolic health and wellbeing program are already currently running in collaboration with the UK’s National Health Service with encouraging results to date.

Nemaura is utilizing its sensor in the form of proBEAT whereby sensor data and numerous other inputs by the users on the BEAT diabetes app is gathered, and AI is used to provide regular feedback and personalized programs for the user, either electronically or through assigned coaches, to provide a gradual and sustainable impact on behavioral change.